Study: Topical Cream Reduces Erythema Associated With Rosacea
Topical oxymetazoline cream 1.0% (Rhofade) effectively treated patients with moderate to severe erythema of rosacea, according to the findings of a recent study published in the Journal of American Academy of Dermatology.
The researchers analyzed data from 2 identically designed phase 3 trials, which randomly assigned 885 patients to receive once daily oxymetazoline or vehicle for 29 days followed by a 28 day follow-up period. The primary outcome was the proportion of patients who achieved a 2 or greater improvement in Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) scores at 3, 6, 9, and 12 hours posttreatment and on day 29 compared with baseline.
Overall, significantly more patients who received oxymetazoline achieved a grade 2 or greater improvement on CEA and SSA scores compared with those in the vehicle group. Oxymetazoline showed greater improvements in individual CEA and SSA scores and digital image analysis of facial erythema compared with vehicle.
In addition, the incidence of treatment-emergent adverse events was low, with 16.4% of patients treated with oxymetazoline and 11.8% of patients treated with vehicle experiencing an adverse event. During the follow-up period, no clinically relevant worsening of erythema was observed.
“Oxymetazoline effectively reduced moderate to severe persistent facial erythema of rosacea and was well tolerated,” the researchers concluded.
Stein-Gold L, Kircik LH, Draelos ZD, et al. Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the two phase 3, 29-day, randomized, controlled REVEAL trials [published online February 4, 2018]. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.01.028.